AtriCure Inc.
ATRC | NASDAQ
$58.32
+$0.22 (+0.38%)
At close: Sep 21, 2026, 4:00 PM ET
$58.50
+$0.18 (+0.31%)
Pre-market:
Sep 22, 2026, 4:37 AM ET
Company Profile
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
Key Executives
| Name | Position |
|---|---|
| Michael H. Carrel | Chief Executive Officer, President & Director |
| Angela L. Wirick | Chief Financial Officer |
| Douglas J. Seith | Chief Operating Officer |
| Karl S. Dahlquist CCEP | Chief Legal Officer |
| Justin J. Noznesky | Chief Marketing & Strategy Officer |
| Salvatore Privitera | Chief Technical Officer |
| Valerie Storch-Willhaus | Vice President of Corporate Marketing & Communications |
| Vinayak Doraiswamy | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 04, 2026 | 4 | Filing |
| Aug 26, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 07, 2026 | 4 | Filing |
| Aug 07, 2026 | 4 | Filing |
| Aug 03, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
| Jul 27, 2026 | S-8 | Filing |
AtriCure Inc.
| Country | United States |
| IPO Date | Aug 4, 2005 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 1,350 |
| CEO | Michael H. Carrel |
Contact Details
7555 Innovation Way Mason,
Ohio 45040 United States
Stock Details
| Ticker Symbol | ATRC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001323885 |
| CUSIP Number | 04963C209 |
| ISIN Number | US04963C2098 |
| SIC Code | 3841 |
Recent News
- 8 days ago / zacks.comIs AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?
- 12 days ago / zacks.comDo Options Traders Know Something About AtriCure Stock We Don't?
- 13 days ago / zacks.comAtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?
- 26 days ago / zacks.comIs AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
- 1 month ago / seekingalpha.comAtriCure: Promising Cardiovascular Surgical Platform
- 1 month ago / marketbeat.comAtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
- 1 month ago / gurufocus.comA Look at AtriCure Inc (ATRC) After 3.1% Gain -- GF Value $39.42 vs Price $42.95
- 2 months ago / fool.comTwo AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
- 2 months ago / fool.comAn AtriCure Director Sold $905,000 in Stock. Here's How to Read It
- 2 months ago / gurufocus.comA Look at AtriCure Inc (ATRC) After 6.0% Decline -- GF Value $39.32 vs Price $37.76
Add to Watchlist
Select watchlists to add or remove ATRC